Improving Access to Care through Telehealth (Health Services Research &...
(Source: Health Services Research & Development) July 2016 Telehealth uses electronic communications to exchange medical information from one site to another. Some of the services that can be...
View ArticleBRIEF-Actelion says initiates phase III study to evaluate macitentan...
* Says initiates phase III study to evaluate macitentan (opsumit) in children with pulmonary arterial hypertension. Source text for Eikon:...
View ArticlevTv Therapeutics Announces Phase 2b Azeliragon Data Selected for Oral...
vTv Therapeutics Announces Phase 2b Azeliragon Data Selected for Oral Presentation at the 2016 Alzheimer’s Association International Conference Azeliragon MOA designed to inhibit RAGE, which affects Aβ...
View ArticleIntra-Cellular Therapies Announces Initiation of ITI-007-201 Phase 3 Clinical...
(Source: Intra-Cellular Therapies Inc) NEW YORK, June 28, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics...
View ArticleIntra-Cellular Therapies Reports Completion of Enrollment of ITI-007-302...
(Source: Intra-Cellular Therapies Inc) NEW YORK, June 30, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics...
View ArticleSage Reports Positive Top-line Results Including Demonstration of 30-Day...
(Source: Sage Therapeutics Inc) Primary endpoint achieved with statistical significance at 60 hours maintained through 30 days 70% remission achieved at 60 hours of SAGE-547 treatment and maintained at...
View ArticleSage Reports Positive Top-line Results Including Demonstration of 30-Day...
Sage Reports Positive Top-line Results Including Demonstration of 30-Day Durability from Phase 2 Clinical Trial of SAGE-547 in Severe Postpartum Depression Primary endpoint achieved with statistical...
View ArticleActelion initiates Phase III study to evaluate macitentan (Opsumit) in...
(Source: Actelion Ltd) Phase III study TOMORROW aims to show the long-term benefits of macitentan (Opsumit) in children with pulmonary arterial hypertension (PAH) Global program has received...
View ArticleActelion to enter Phase II clinical development with new dual orexin receptor...
(Source: Actelion Ltd) Investor webcast to provide background information on Actelion's new DORA to be broadcast 07 July 2016 at 14:00 hrs CEST ALLSCHWIL, SWITZERLAND - 07 July 2016 - Actelion Ltd...
View ArticleAxovant Sciences Announces Presentations and Sponsored Symposium at the 2016...
(Source: Axovant Sciences Ltd) Axovant Sciences Announces Presentations and Sponsored Symposium at the 2016 Alzheimer's Association International Conference HAMILTON, Bermuda, July 18, 2016...
View ArticleStudy: Cancer Drug Restores Brain Dopamine, Reduces Toxic Proteins in...
(Source: GUMC - Georgetown University Medical Center) WASHINGTON (July 11, 2016) - A small phase I study provides molecular evidence that an FDA-approved drug for leukemia significantly increased brain...
View ArticleEuropean Commission Approves Extended Indication For Amgen's Kyprolis®...
(Source: Amgen Inc) THOUSAND OAKS, Calif., July 3, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a variation to the marketing authorization for...
View ArticleGlobal Blood Therapeutics Announces Publication of Preclinical GBT440 Results...
(Source: Global Blood Therapeutics Inc) SOUTH SAN FRANCISCO, Calif., July 8, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel...
View ArticleXBiotech Presents Pivotal Phase III Data Showing Xilonix(TM) Demonstrated...
(Source: XBiotech Inc) (GLOBE NEWSWIRE via COMTEX) --- Improved clinical response seen for multiple symptoms associated with disease progression and overall survival, with notable lack of toxicity -...
View ArticleAllergan and Adamas Announce New Expanded Indication for NAMZARIC® (Memantine...
(Source: Allergan plc) DUBLIN, July 19, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), today announced that the U.S. Food and Drug Administration (FDA)...
View ArticleAllergan and Adamas Announce New Expanded Indication for NAMZARIC® (Memantine...
(Source: Adamas Pharmaceuticals Inc) DUBLIN, July 19, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), today announced that the U.S. Food and Drug...
View ArticleXBiotech Presents Pivotal Phase III Data Showing Xilonix™ Demonstrated...
(Source: XBiotech Inc) Improved clinical response seen for multiple symptoms associated with disease progression and overall survival, with notable lack of toxicity Xilonix is the first antibody...
View ArticleAnavex to Present at the Alzheimer’s Association International Conference...
NEW YORK, July 12, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for...
View ArticleAngionetics & A Huapont Life Sciences (China) Affiliate Enter Into Equity...
(Source: Taxus Cardium Pharmaceuticals Group Inc) SAN DIEGO, July 11, 2016 /PRNewswire/ -- Angionetics Inc., a wholly-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol:...
View ArticleInitiation of Phase 1 Clinical Study with Novel Immuno-Oncology Candidate...
(Source: Sosei Group Corporation) b01ce187-e6bd-4b0f-87f4-3319115b1bea.pdf Initiation of Phase 1 Clinical Study with Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment from...
View Article